查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600163

神經保護市場：按產品、治療、給藥途徑、應用和最終用戶 - 全球預測 2025-2030

Neuroprotection Market by Product, Treatment, Route of Administration, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年神經保護市場價值為2,909.8億美元，預估2024年將達3,117.9億美元，複合年成長率為7.63%，至2030年將達4,868.9億美元。

神經保護是指在面對急性或慢性神經退化性疾病時維持神經元結構和功能的策略和機制。隨著世界人口老化，阿茲海默症、帕金森氏症和中風等神經退化性疾病的發生率不斷增加，因此需要進行神經保護干預。神經保護應用涵蓋藥品、生物技術產品和生活方式干涉，最終用途為醫院、研究機構和學術實驗室。市場洞察指出，由於基因組學和藥物發現的持續研究、對個人化醫療的興趣日益濃厚以及政府在醫療保健方面的資金增加，其範圍正在擴大。 CRISPR 和基因治療等技術進步是重要的成長動力。人工智慧在攜帶式診斷工具和預測分析中的興起也帶來了巨大的機會。主要影響因素包括對非侵入性治療方案的需求和新型藥物傳輸系統的快速發展。然而，市場面臨臨床測試高成本、監管障礙以及神經保護藥物潛在副作用等挑戰。此外，缺乏長期結果的綜合資料集。對於公司來說，一條有價值的前進道路是專注於創新策略，例如開發跨越血腦障壁的小分子藥物以及利用機器學習演算法對患者進行分層。多標靶藥物和聯合治療的研究和開發有可能顯著提高治療效果。生物技術公司和學術機構之間的創新合作可以加速發現並創造競爭。專注於強大的資料分析和遵守新的法規結構可以減少市場進入障礙。神經保護市場呈現廣泛的成長潛力，特別是隨著市場開拓的擴大，但持續成長和保持相關性需要仔細規避現有限制並專注於科學進步和市場差異化，戰略重點至關重要。

主要市場統計
基準年[2023] 2909.8億美元
預測年份 [2024] 3117.9億美元
預測年份 [2030] 4868.9億美元
複合年成長率（%） 7.63%

市場動態：揭示快速發展的神經保護市場的關鍵市場洞察

供需的動態交互作用正在改變神經保護市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 神經退化性疾病盛行率的上升增加了對神經保護療法的需求
    • 更重視預防醫學和生活方式的改變，以減少危險因素
    • 提高醫療專業人員和患者對神經系統疾病的認知
  • 市場限制因素
    • 血腦障壁的複雜性限制了神經保護劑的傳遞和功效
  • 市場機會
    • 增加研發投資以開發非侵入性和預防性神經保護策略
    • 開發個人化的神經保護療法和可客製化的治療計劃
  • 市場問題
    • 嚴格的監管要求阻礙了神經保護療法的開發和核准

波特五力：駕馭神經保護市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解神經保護市場的外部影響

外部宏觀環境因素在塑造神經保護市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解神經保護市場的競爭格局

對神經保護市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：神經保護市場供應商的績效評估

FPNV定位矩陣是評估神經保護市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃神經保護市場的成功之路

神經保護市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 神經退化性疾病盛行率的上升增加了對神經保護療法的需求
      • 更重視預防醫學和生活方式的改變，以減少危險因素
      • 提高醫療保健專業人員和患者對神經系統疾病的認知
    • 抑制因素
      • 血腦障壁的複雜性限制了神經保護劑的傳遞和功效
    • 機會
      • 增加研發投資，制定非侵入性和預防性神經保護策略
      • 開發個人化的神經保護療法和可客製化的治療計劃
    • 任務
      • 嚴格的監管要求阻礙了神經保護療法的開發和核准
  • 市場區隔分析
    • 產品：增加細胞凋亡抑制劑的使用以維持神經元存活並防止神經退化的進展
    • 應用：具有健康意識的消費者越來越偏好神經保護性預防
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章神經保護市場：依產品

  • 介紹
  • 凋亡抑制劑
  • 遊離發炎劑
  • 麩胺酸拮抗劑
  • 金屬離子螯合劑
  • 神經營養因子
  • 自由基清除劑
  • 興奮劑

第7章神經保護市場：依治療分類

  • 介紹
  • 阿茲海默症
  • 肌萎縮側索硬化症
  • 腦損傷
  • 亨丁頓舞蹈症
  • 多發性硬化症
  • 神經病變
  • 眼睛退化
  • 帕金森氏症

第8章神經保護市場：依給藥途徑

  • 介紹
  • 椎管內的
  • 靜脈
  • 口服
  • 經皮的

第9章神經保護市場：依應用分類

  • 介紹
  • 預防
  • 治療

第10章神經保護市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 診所
  • 醫院
  • 製藥和生物技術公司

第11章美洲神經保護市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太神經保護市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的神經保護市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 波士頓科學公司收購 Silk Road Medical 以獲得尖端 TCAR 技術，加強神經血管產品組合
    • Silk Road Medical 推出 Enroute plus 經頸動脈系統，重點在於神經保護
    • Astracy Pharmaceuticals 開始缺血性中風治療 AST-004 的 2 期測試並向前推進
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Abcam PLC by Danaher Corporation
  • Anavex Life Sciences corp.
  • AstraZeneca PLC
  • Astrocyte Pharmaceuticals Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb Company（BMS）
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-430D42AA0F33

The Neuroprotection Market was valued at USD 290.98 billion in 2023, expected to reach USD 311.79 billion in 2024, and is projected to grow at a CAGR of 7.63%, to USD 486.89 billion by 2030.

Neuroprotection refers to strategies and mechanisms aimed at preserving the structure and function of neurons in the face of acute or chronic neurodegenerative insults. The necessity of neuroprotective interventions arises from the increasing incidence of neurodegenerative diseases like Alzheimer's, Parkinson's, and stroke due to the aging global population. The application of neuroprotection spans pharmaceuticals, biotechnology products, and lifestyle interventions, with end-use seen in hospitals, research, and academic laboratories. Market insight points to an expanding scope due to ongoing research in genomics and drug discovery, burgeoning interest in personalized medicine, and increased governmental funding in healthcare. Technological advancements, such as CRISPR and gene therapy, are significant growth drivers. The rise of portable diagnostic tools and AI in predictive analytics also presents major opportunities. Key influencing factors include the demand for non-invasive treatment options and the rapid development of novel drug delivery systems. However, the market faces challenges like high costs of clinical trials, regulatory hurdles, and potential side effects of neuroprotective drugs. Additionally, there is a shortage of comprehensive datasets for long-term outcomes. For businesses, a focus on innovative strategies such as developing small-molecule drugs that cross the blood-brain barrier and leveraging machine learning algorithms for patient stratification are valuable pathways. Research and development into multi-target drugs or combination therapies could significantly enhance therapeutic efficacy. Innovative collaborations between biotech firms and academic institutions could accelerate discoveries, providing a competitive edge. Emphasizing robust data analysis and compliance with emerging regulatory frameworks will ease market entry barriers. While the neuroprotection market shows promising growth potential, particularly with expanding therapeutic development, careful navigation around existing limitations and a strategic focus on scientific advancement and market differentiation are essential for sustained growth and relevance.

KEY MARKET STATISTICS
Base Year [2023] USD 290.98 billion
Estimated Year [2024] USD 311.79 billion
Forecast Year [2030] USD 486.89 billion
CAGR (%) 7.63%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuroprotection Market

The Neuroprotection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
    • Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
    • Increased awareness among healthcare professionals and patients about neurological conditions
  • Market Restraints
    • Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
  • Market Opportunities
    • Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
    • Development of personalized neuroprotective therapies and customizable treatment plans
  • Market Challenges
    • Stringent regulatory requirements hindering the development and approval of neuroprotective therapies

Porter's Five Forces: A Strategic Tool for Navigating the Neuroprotection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuroprotection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuroprotection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuroprotection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuroprotection Market

A detailed market share analysis in the Neuroprotection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuroprotection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuroprotection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuroprotection Market

A strategic analysis of the Neuroprotection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroprotection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam PLC by Danaher Corporation, Anavex Life Sciences corp., AstraZeneca PLC, Astrocyte Pharmaceuticals Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Company (BMS)., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Neuren Pharmaceuticals, Novartis AG, Pfizer Inc., Reata Pharmaceuticals, Inc., Sage Therapeutics, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroprotection Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Apoptosis Inhibitors, Free Anti-Inflammatory Agents, Glutamate Antagonists, Metal Ion Chelators, Neurotrophic Factors, Radical Trapping Agents, and Stimulants.
  • Based on Treatment, market is studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease, Multiple Sclerosis, Neuropathies, Ocular Degeneration, and Parkinson's Disease.
  • Based on Route of Administration, market is studied across Intrathecal, Intravenous, Oral, and Transdermal.
  • Based on Application, market is studied across Prevention and Treatment.
  • Based on End Users, market is studied across Academic & Research Institutes, Clinics, Hospitals, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
      • 5.1.1.2. Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
      • 5.1.1.3. Increased awareness among healthcare professionals and patients about neurological conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
      • 5.1.3.2. Development of personalized neuroprotective therapies and customizable treatment plans
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements hindering the development and approval of neuroprotective therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing utilization of apoptosis inhibitors to maintain neuronal survival and prevent the progression of neurodegeneration
    • 5.2.2. Application: Growing preference for prevention of neuroprotection among health-conscious consumers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuroprotection Market, by Product

  • 6.1. Introduction
  • 6.2. Apoptosis Inhibitors
  • 6.3. Free Anti-Inflammatory Agents
  • 6.4. Glutamate Antagonists
  • 6.5. Metal Ion Chelators
  • 6.6. Neurotrophic Factors
  • 6.7. Radical Trapping Agents
  • 6.8. Stimulants

7. Neuroprotection Market, by Treatment

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Amyotrophic Lateral Sclerosis
  • 7.4. Brain Injury
  • 7.5. Huntington's Disease
  • 7.6. Multiple Sclerosis
  • 7.7. Neuropathies
  • 7.8. Ocular Degeneration
  • 7.9. Parkinson's Disease

8. Neuroprotection Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intrathecal
  • 8.3. Intravenous
  • 8.4. Oral
  • 8.5. Transdermal

9. Neuroprotection Market, by Application

  • 9.1. Introduction
  • 9.2. Prevention
  • 9.3. Treatment

10. Neuroprotection Market, by End Users

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Clinics
  • 10.4. Hospitals
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Americas Neuroprotection Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Neuroprotection Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Neuroprotection Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Boston Scientific to enhance neurovascular portfolio with Silk Road Medical acquisition for cutting-edge TCAR technology
    • 14.3.2. Silk Road Medical's introduction of the Enroute plus transcarotid system emphasizing neuroprotection
    • 14.3.3. Astrocyte Pharmaceuticals moves forward with AST-004 as it enters phase 2 trials for ischemic stroke treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abcam PLC by Danaher Corporation
  • 3. Anavex Life Sciences corp.
  • 4. AstraZeneca PLC
  • 5. Astrocyte Pharmaceuticals Inc.
  • 6. Bayer AG
  • 7. Biogen Inc.
  • 8. Bristol Myers Squibb Company (BMS).
  • 9. Daiichi Sankyo Company, Limited
  • 10. Eisai Co., Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck & Co., Inc.
  • 17. Neuren Pharmaceuticals
  • 18. Novartis AG
  • 19. Pfizer Inc.
  • 20. Reata Pharmaceuticals, Inc.
  • 21. Sage Therapeutics, Inc.
  • 22. Sangamo Therapeutics, Inc.
  • 23. Sanofi S.A.
  • 24. Sunovion Pharmaceuticals Inc
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. NEUROPROTECTION MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROPROTECTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROPROTECTION MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. TAIWAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. THAILAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. VIETNAM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. DENMARK NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EGYPT NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FINLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. FRANCE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. GERMANY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ISRAEL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. ITALY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NIGERIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. NORWAY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. POLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. QATAR NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. RUSSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SPAIN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWEDEN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. TURKEY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 246. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 247. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023